Prof Petrylak talks with ecancer at the Best of ASCO 2017 meeting in Miami about the early use of the CYP17A1 inhibitor, abiraterone, for patients with metastatic, hormone sensitive, prostate cancer. He goes on to discuss the data from, and the...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uhE9Jc
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: April 2017 Source: European Journal of Cancer, Volume 75 Author(s): A. Ieni, G. Angelico, P. Zeppa, G. Tuccari fro...
-
Objective A systematic review and meta-analysis to investigate the impact of electronic nicotine delivery systems (ENDS) and/or electronic n...
-
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers British Journal of Cancer 116, 1425 (23 May 2017). ...
-
Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. ...
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Shehwaz Anwar, Hina Youn...
-
Abstract The quantitative evaluation of Social Science and Humanities (SSH) and the investigation of the existing similarities between SSH...
-
Sporadic Salmonella outbreaks with varying clinical presentations have been on the rise in various parts of Uganda. The sources of outbreaks...
-
Abstract Purpose Complete mesocolic excision (CME) with central vascular ligation (CVL) has been widely accepted as a surgical treatment...
-
Ecohydrological responses to climate change will exhibit spatial variability and understanding the spatial pattern of ecological impacts is ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου